Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2,5-dimethoxy-4-propylamphetamine
- Development stage
- Preclinical
- Lead developer
- University of California, San Diego
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
2,5-Dimethoxy-4-propylamphetamine (DOPR) is a psychedelic phenethylamine and substituted amphetamine derivative of the DOx family. Originally synthesized by Alexander Shulgin, DOPR acts as a potent agonist of the serotonin 5-HT2 receptors, particularly 5-HT2A and 5-HT2C. It is being investigated preclinically by the University of California San Diego and Gilgamesh Pharmaceuticals for its potential to treat neuropsychiatric disorders characterized by amotivated states, such as depression and schizophrenia. Preclinical studies in mice have demonstrated that low, sub-hallucinogenic doses (microdoses) of DOPR can significantly increase effortful motivation without inducing the head-twitch response associated with hallucinogenic effects.
- Other names
- 2,5-dimethoxy-4-propylamphetamine hydrochloride4-propyl-2,5-dimethoxyamphetamineDOPRDOPR hydrochloride
02
Targets
HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)
Beyond the preview
Go deeper on 2,5-dimethoxy-4-propylamphetamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 2,5-dimethoxy-4-propylamphetamine.